title: [A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14].
authors.affiliation: AUO Geschäftsstelle, MeckEvidence - Dienstleistungen für medizinische Dokumentation und Forschung, Seestr. 11, 17252, Schwarz, Deutschland. AUO@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
authors.affiliation: Städtisches Klinikum Braunschweig, Braunschweig, Deutschland.
authors.forename: P
authors.initials: P
authors.lastname: Hammerer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D004311:Double-Blind Method; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015990:Placebo Effect; D015995:Prevalence; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D012307:Risk Factors; D015996:Survival Rate; D013867:Thiohydantoins / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013867:Thiohydantoins; C572045:apalutamide